Literature DB >> 11207629

Choosing an oestrogen replacement therapy in young adult women with Turner syndrome.

H Guttmann1, Z Weiner, E Nikolski, S Ish-Shalom, J Itskovitz-Eldor, M Aviram, S Reisner, Z Hochberg.   

Abstract

OBJECTIVE: Hormone replacement therapy (HRT) is prescribed to most patients with Turner syndrome (TS) although its use in adult TS patients has not been scientifically evaluated. The present study was performed to compare the short-term effects in adult women with Turner syndrome of low-dose oral conjugated oestrogen (0.625 mg, CE) with relatively high dose ethinyl oestradiol (30 microg, EE2); both combined with an oral progestin. DESIGN AND PATIENTS: After 4 months off HRT, 17 young, otherwise healthy women with TS were enrolled in a random, unblinded, crossover study of the two oestrogenic preparations, each given for 6 months. MEASUREMENTS: We compared parameters of oestrogenic activity that would cover immediate changes in hormone levels, biochemistry, bone turnover, uterine and cardiac variables, which constitute risk factors for later development of diabetes, atherosclerosis, osteoporosis and aortic dissection.
RESULTS: Serum FSH returned to normal follicular phase levels only on the EE2 regimen. The hypotrophic endometria normalized with either of the two oestrogen regimens with no excessive hypertrophy. Hyperinsulinaemia was suppressed to normal by both EE2 and CE. PTH and 1,25-dihydroxyvitamin D levels increased on HRT (EE2 > CE), and phosphorus decreased. Alkaline phosphatase, osteocalcin and urinary deoxypyridinoline cross-links (DPD) were high off therapy; the former two suppressed to high-normal levels on the EE2 regimen, but not on CE, and DPD did not normalize with either HRT. Lipid profiles in these young TS patients were normal. Liver enzymes were mildly elevated off therapy and suppressed to normal levels on both regimens, but more so with EE2.
CONCLUSIONS: The risk factors embodied in hyperinsulinaemia and enhanced bone turnover which, ultimately, have consequences for TS morbidity, are minimized by HRT. In the short term, neither regimen is effective for bone turnover in adult women with Turner syndrome.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11207629     DOI: 10.1046/j.1365-2265.2001.01181.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  5 in total

Review 1.  Sex hormone replacement in Turner syndrome.

Authors:  Christian Trolle; Britta Hjerrild; Line Cleemann; Kristian H Mortensen; Claus H Gravholt
Journal:  Endocrine       Date:  2011-12-07       Impact factor: 3.633

Review 2.  Effect of estrogen replacement therapy on bone and cardiovascular outcomes in women with turner syndrome: a systematic review and meta-analysis.

Authors:  Dahima Cintron; Rene Rodriguez-Gutierrez; Valentina Serrano; Paula Latortue-Albino; Patricia J Erwin; Mohammad Hassan Murad
Journal:  Endocrine       Date:  2016-07-29       Impact factor: 3.633

3.  Trajectories of metabolic parameters after bilateral oophorectomy in premenopausal women.

Authors:  Ekta Kapoor; Stephanie S Faubion; Liliana Gazzuola Rocca; Michelle M Mielke; Carin Y Smith; Walter A Rocca
Journal:  Maturitas       Date:  2022-07-21       Impact factor: 5.110

Review 4.  Hormone therapy for uterine and endometrial development in women with premature ovarian insufficiency.

Authors:  Laurentiu Craciunas; Nikolaos Zdoukopoulos; Suganthi Vinayagam; Lamiya Mohiyiddeen
Journal:  Cochrane Database Syst Rev       Date:  2022-10-06

5.  Peri- and postmenopause-diagnosis and interventions interdisciplinary S3 guideline of the association of the scientific medical societies in Germany (AWMF 015/062): short version.

Authors:  Olaf Ortmann; Maria J Beckermann; Elisabeth C Inwald; Thomas Strowitzki; Eberhard Windler; Clemens Tempfer
Journal:  Arch Gynecol Obstet       Date:  2020-07-13       Impact factor: 2.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.